,32,33 Thus, combinatory treatments with CpG-Stat3 siRNA and CTLA4 or PD-1 antibody may significantly boost the antitumor efficacies of CTLA4 or PD-1 antibody in treating B cell lymphoma and melanoma. This evidence concerns the gene STAT3 and B-cell non-Hodgkin lymphoma.